Fluorescent A2A and A3 adenosine receptor antagonists as flow cytometry probes.
Purinergic Signal
; 19(3): 565-578, 2023 09.
Article
em En
| MEDLINE
| ID: mdl-35687212
ABSTRACT
Adenosine receptor (AR) ligands are being developed for metabolic, cardiovascular, neurological, and inflammatory diseases and cancer. The ease of drug discovery is contingent on the availability of pharmacological tools. Fluorescent antagonist ligands for the human A2A and A3ARs were synthesized using two validated pharmacophores, 1,3-dipropyl-8-phenylxanthine and triazolo[1,5-c]quinazolin-5-yl)amine, which were coupled to eight reporter fluorophores AlexaFluor, JaneliaFluor (JF), cyanine, and near infrared (NIR) dyes. The conjugates were first screened using radioligand binding in HEK293 cells expressing one of the three AR subtypes. The highest affinities at A2AAR were Ki 144-316 nM for 10, 12, and 19, and at A3AR affinity of Ki 21.6 nM for 19. Specific binding of JF646 conjugate MRS7774 12 to the HEK293 cell surface A2AAR was imaged using confocal microscopy. Compound 19 MRS7535, a triazolo[1,5-c]quinazolin-5-yl)amine containing a Sulfo-Cy7 NIR dye, was suitable for A3AR characterization in whole cells by flow cytometry (Kd 11.8 nM), and its bitopic interaction mode with an A3AR homology model was predicted. Given its affinity and selectivity (11-fold vs. A2AAR, ~ 50-fold vs. A1AR and A2BAR) and a good specific-to-nonspecific binding ratio, 19 could be useful for live cell or potentially a diagnostic in vivo NIR imaging tool and/or therapy targeting the A3AR.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Antagonistas de Receptores Purinérgicos P1
/
Corantes Fluorescentes
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Purinergic Signal
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos